PMID- 34095900
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
VI  - 4
IP  - 3
DP  - 2021 Dec
TI  - Impact of Using Median vs. Mean in Calculating ERBB2 FISH Results in Breast 
      Cancer.
PG  - 87-96
AB  - INTRODUCTION: Erb-b2 receptor tyrosine kinase 2 (ERBB2) testing is used to 
      measure the status of ERBB2 gene expression and DNA amplification. Test results 
      have been reported with a discrepancy as high as 20%. The purpose of this study 
      was to improve ERBB2 fluorescence in situ hybridization (FISH) sensitivity by 
      evaluating results generated by median as well as mean calculations. METHODS: We 
      retrospectively identified breast cancer cases at our institution in which ERBB2 
      FISH testing was performed in-house from June 2018 to May 2020. FISH results were 
      classified using the 2018 American Society of Clinical Oncology/College of 
      American Pathologists guidelines: groups 1 and 5 are FISH positive and negative, 
      respectively, and groups 2-4 are equivocal requiring additional work-up. FISH 
      counting sheets were collected and regrouped by median ERBB2 copy number counts 
      and median ERBB2/CEP17 ratio and compared with the mean ERBB2 and mean 
      ERBB2/CEP17 ratio. Intra-tumor genetic heterogeneity and CEP17 copy number gain 
      (CEP17 >/=3) were assessed to see if they affect the discrepancy between median and 
      mean groups. RESULTS: Seventy-two breast cancer cases were collected and 
      evaluated. Eleven cases (11 of 72 [15%]) had discrepant grouping by mean and 
      median calculations. A significant number of discrepancies were found for CEP17 
      copy number gain (p = 0.027) but not for ERBB2 (p = 0.411), the ERBB2/CEP17 ratio 
      (p = 0.445), FISH results (p = 0.194), or genetic heterogeneity (p = 0.465). 
      Among the four cases regrouped to median group 1, 2 were from mean group 3 and 
      underwent anti-ERBB2 targeted therapy and 2 were from mean groups 4 and 5 may 
      have benefitted from targeted therapy with more than 30% amplified cells. The 
      median may be better to reflect the monosomy subclone within tumor tissues for 
      the case 387 moved from mean group 5 to median group 2. The 6 cases moved from 
      mean group 5 to median group 4 with CEP17 copy number gain may have had a poor 
      prognosis based on other study result. CONCLUSION: Including the median 
      calculation may increase ERBB2 sensitivity and identification of CEP17 copy 
      number gain. Further clinical studies are necessary to examine the outcome of 
      including median in calculating ERBB2/CEP17 values.
FAU - Song, Jie
AU  - Song J
AD  - Program in Diagnostic Genetics and Genomics, School of Health Professions, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Yu, Alexander
AU  - Yu A
AD  - School of Medicine, The University of Texas Medical Branch, Galveston, Texas, 
      USA.
FAU - Munoz, Diana
AU  - Munoz D
AD  - Health Information Management, Houston Methodist, Houston, Texas, USA.
FAU - Han, Song
AU  - Han S
AD  - Department of Pathology, The University of Texas Medical Branch, Galveston, 
      Texas, USA.
FAU - Nimmakayalu, Manjunath
AU  - Nimmakayalu M
AD  - Program in Diagnostic Genetics and Genomics, School of Health Professions, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Hu, Peter C
AU  - Hu PC
AD  - Program in Diagnostic Genetics and Genomics, School of Health Professions, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Dong, Jianli
AU  - Dong J
AD  - Department of Pathology, The University of Texas Medical Branch, Galveston, 
      Texas, USA.
LA  - eng
GR  - TL1 TR001440/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20210415
PL  - India
TA  - Cancer Med J
JT  - Cancer medicine journal
JID - 101744997
PMC - PMC8171267
MID - NIHMS1695277
OTO - NOTNLM
OT  - Breast cancer
OT  - CEP17
OT  - ERBB2
OT  - FISH
OT  - Mean
OT  - Median
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
PMCR- 2021/12/01
CRDT- 2021/06/07 06:15
PHST- 2021/06/07 06:15 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
PST - ppublish
SO  - Cancer Med J. 2021 Dec;4(3):87-96. Epub 2021 Apr 15.